Chester County News and Community Website
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) reported new peer-reviewed findings demonstrating that its investigational DNA immunotherapy, INO-3107, continues to deliver long-term clinical benefits for patients with recurrent respiratory papillomatosis …
INOVIO’s INO-3107 Shows Sustained Long-Term Benefits for Patients With Recurrent Respiratory Papillomatosis Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) will release its second-quarter 2025 financial results after the market closes on Tuesday, August 12. The company will host a conference call and …
INOVIO to Announce Q2 2025 Results on August 12 Read More
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) announced it will present on its next-generation DNA medicine technology for rare diseases at the upcoming Orphan Drug Summit in Boston, Massachusetts.
INOVIO to Present DNA Medicine Innovations for Rare Diseases at Orphan Drug Summit Read More PLYMOUTH MEETING, PA — INOVIO Pharmaceuticals, Inc. (Nasdaq: INO) has announced plans to conduct an underwritten public offering of its common stock, or pre-funded warrants in lieu of common stock, …
INOVIO Announces Public Offering of Common Stock and Warrants Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has released its financial results for the first quarter of 2025, alongside significant updates on its pipeline advancements, including the upcoming Biologics License …
INOVIO Reports Q1 2025 Results and Key Developments in DNA Medicines Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced its participation in a series of high-profile conferences in May, where it will showcase pivotal data on its lead DNA immunotherapy …
INOVIO to Present Key Clinical Data at Major Scientific Conferences Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced its participation in several prominent conferences, where it will present significant findings related to its lead candidate, INO-3107. The presentations will …
INOVIO to Showcase Breakthrough Data on INO-3107 at Major Industry Conferences Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) released its financial results and operational highlights for 2024, marking significant strides in its pipeline and the broader development of DNA medicines.
INOVIO Reports Progress on INO-3107 and DNA Medicine, 2024 Financial Outcomes Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced notable interim findings from a Phase 1 clinical trial testing DNA-encoded monoclonal antibodies (DMAbs) for COVID-19. Impressively, 100% of participants who reached …
INOVIO Reports Groundbreaking Results in COVID-19 Antibody Trial Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has unveiled promising peer-reviewed results from its Phase 1/2 clinical trial for INO-3107, a cutting-edge DNA medicine designed to treat recurrent respiratory papillomatosis (RRP). …
INOVIO’s INO-3107 Shows Powerful Potential for Treating Recurrent Respiratory Papillomatosis Read More